Literature DB >> 18056378

Biochemical and folding defects in a RAG1 variant associated with Omenn syndrome.

Carrie Simkus1, Priyanka Anand, Anamika Bhattacharyya, Jessica M Jones.   

Abstract

The RAG1 and RAG2 proteins are required to assemble mature Ag receptor genes in developing lymphocytes. Hypomorphic mutations in the gene encoding RAG1 are associated with Omenn syndrome, a primary immunodeficiency. We explored the biochemical defects resulting from a mutation identified in an Omenn syndrome patient which generates an amino acid substitution in the RAG1 RING finger/ubiquitin ligase domain (C325Y in murine RAG1) as well as an adjacent substitution (P326G). RAG1 C325Y demonstrated a 50-fold reduction in recombination activity in cultured pro-B cells despite the fact that its expression and localization to the nucleus were similar to the wild-type protein. The C325Y substitution severely abrogated ubiquitin ligase activity of the purified RAG1 RING finger domain, and the tertiary structure of the domain was altered. The P326G substitution also abrogated ubiquitin ligase activity but had a less severe effect on protein folding. RAG1 P326G also demonstrated a recombination impairment that was most pronounced when RAG1 levels were limiting. Thus, a correctly folded RAG1 RING finger domain is required for normal V(D)J recombination, and RAG1 ubiquitin ligase activity can contribute when the protein is present at relatively low levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056378     DOI: 10.4049/jimmunol.179.12.8332

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  RAG1-mediated ubiquitylation of histone H3 is required for chromosomal V(D)J recombination.

Authors:  Zimu Deng; Haifeng Liu; Xiaolong Liu
Journal:  Cell Res       Date:  2015-01-09       Impact factor: 25.617

2.  Noncore RAG1 regions promote Vβ rearrangements and αβ T cell development by overcoming inherent inefficiency of Vβ recombination signal sequences.

Authors:  Julie E Horowitz; Craig H Bassing
Journal:  J Immunol       Date:  2014-01-10       Impact factor: 5.422

Review 3.  Ubiquitin-Modifying Enzymes and Regulation of the Inflammasome.

Authors:  Michael G Kattah; Barbara A Malynn; Averil Ma
Journal:  J Mol Biol       Date:  2017-10-13       Impact factor: 5.469

4.  Requirement for ubiquitin conjugation and 26S proteasome activity at an early stage in V(D)J recombination.

Authors:  Anamika Bhattacharyya; Jessica M Jones
Journal:  Mol Immunol       Date:  2010-02-08       Impact factor: 4.407

5.  VprBP binds full-length RAG1 and is required for B-cell development and V(D)J recombination fidelity.

Authors:  Michele D Kassmeier; Koushik Mondal; Victoria L Palmer; Prafulla Raval; Sushil Kumar; Greg A Perry; Dirk K Anderson; Pawel Ciborowski; Sarah Jackson; Yue Xiong; Patrick C Swanson
Journal:  EMBO J       Date:  2011-12-13       Impact factor: 11.598

6.  Role of RAG1 autoubiquitination in V(D)J recombination.

Authors:  Samarendra K Singh; Martin Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 7.  Epigenetic regulation of antigen receptor gene rearrangement.

Authors:  Ann J Feeney
Journal:  Curr Opin Immunol       Date:  2011-01-07       Impact factor: 7.486

8.  Diverse phenotypic and genotypic presentation of RAG1 mutations in two cases with SCID.

Authors:  Neslihan Edeer Karaca; Guzide Aksu; Ferah Genel; Nesrin Gulez; Sema Can; Yesim Aydinok; Serap Aksoylar; Emin Karaca; Imren Altuglu; Necil Kutukculer
Journal:  Clin Exp Med       Date:  2009-05-21       Impact factor: 3.984

Review 9.  Human RAG mutations: biochemistry and clinical implications.

Authors:  Luigi D Notarangelo; Min-Sung Kim; Jolan E Walter; Yu Nee Lee
Journal:  Nat Rev Immunol       Date:  2016-03-21       Impact factor: 53.106

10.  Karyopherin alpha 1 is a putative substrate of the RAG1 ubiquitin ligase.

Authors:  Carrie Simkus; Michelle Makiya; Jessica M Jones
Journal:  Mol Immunol       Date:  2008-12-31       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.